Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Core Information for Regulatory Decision Making from a SADC
Regulator’s Perspectivepresented to the
PRE‐ ICDRA Meeting, SingaporeGugu.N. Mahlangu
Protecting Your Right to Quality Medicines
Overview
Protecting Your Right to Quality Medicines
• Medicines Regulatory Processes in Zimbabwe • Decision Making in Registration• Guiding Processes and Challenges• SADC Perspective• Prospects for the future
Protecting Your Right to Quality Medicines
SADC Countries
15 member statesPopulation size : 257, 726,000 Gross Domestic Product (GDP) : 471,118 US$ billion
Source: www.sadc.int
3
Protecting Your Right to Quality Medicines
ZIMBABWEPopulation: 11 651 000GDP: USD6 Billion (2010 est.)
4
Protecting Your Right to Quality Medicines
Medicines Regulatory Processes in Zimbabwe
5
• Administrative Elements: Legislation; Regulations & Policies
• Technical Standards: Guidelines, Quality Manuals, SOPs, Specifications
• Regulatory Functions: Registration; Premises & Persons Licensing; Manufacturer & Distributors inspection; Control of Clinical Trials; Testing of Medicines: Control of Advertising of Medicines, Pharmacoviigilance.
Medicines Regulatory Processes in Zimbabwe
6
Types of Applications: Human and veterinary medicinesRequirements: Applicants submit dossiers, fees, samplesProcessing of applications: GMP inspection of manufacturer; evaluation of dossier; analysis of product sample Approval: Registration Committee (or Vet Committee) after consideration of GMP reports; evaluation reports; analysis reportsAnnual Retention: Registered products have to be retained by payment of annual retention feesEmergency supply of unregistered medicines: section 75 of Act
Protecting Your Right to Quality Medicines
Medicines Regulatory Processes in Zimbabwe
7
• Registration Decisions: Approval or Refuse Registration of a product is made by the Registration Committee (external expert committee) in accordance with Act & Regulations
• Frequency of Meetings: Once every month • Committee chaired by an authority (board) member• The Committee considers: new applications received;
applications for registration; • Execution of Decision: Director‐General through staff• Oversight of Committees: Registration Committee reports to
the Authority quarterly
Protecting Your Right to Quality Medicines
Decision Making in Medicines Registration
8
• MCAZ Registration Guideline (converting to CTD)• SADC Registration Guideline• WHO Norms and Standards, and Guidelines• Registration Committee Policies• Pharmacopeias (PhInt, BP, PhEur, USP)• ICH and VICH Guidelines‐novel products• Desk Research: WHOPAR, WHOPIR, EPAR, USFDA Dockets
Protecting Your Right to Quality Medicines
Guidelines
9
Challenges of guidelines based on well resourced countries, WHO
• Unmatched human resources• Unmatched financial resources• Unmatched knowledge and skills• Processes in dynamic motion
Results in inefficient processes, backlog, out of step with the regulated industry, retards institutional development
Protecting Your Right to Quality Medicines
Decision Making in Medicines Registration
10
Botswana• Considers the registration status of NCEs and biopharmaceuticals in ICH regions
• Consider WHO pre‐qualification status• Guidelines based on ICH,SADC, USFDA, EMA, WHO and TGA guidelines
• Regulatory and legislative framework influenced by updates in these guidelines
Protecting Your Right to Quality Medicines
SADC Countries
11
Mozambique• Considers SADC guidelines• Reviewing entire pharmaceutical legislation to update it
• Review based on reference countries – Portugal, Brazil, and the SADC member states of SA, Zimbabwe and Tanzania
• Collaborating with Zimbabwe/Tanzania on pharmacovigilance and Clinical trials guidelines
Protecting Your Right to Quality Medicines
SADC Countries
12
• Most guidelines reflect/ incorporate SADC requirements• Member states involved in WHO pre‐qualification capacity
building programme• SADC envisions joint evaluation of dossiers; joint inspection;
joint approval of clinical trials• SADC started information exchange through an information
hub • Shared point established for exchange of information• Appropriate framework exists in the Trade Protocol intended
to reduce technical barriers to trade
Protecting Your Right to Quality Medicines
SADC Harmonisation Process
13
• Joint regulatory activities, information exchange and mutual recognition within SADC
• Collaboration with other national medicines regulatory authorities and international agencies
• Establishment of a robust electronic data management system• Conversion to CTD and eventually e‐submissions• Utilisation of outcomes from WHO PQP, USFDA approvals, EU
approvals and approvals by other better resourced regulatory bodies
• Strengthen back monitoring to ensure suppliers stick to • approved sites and processes
Protecting Your Right to Quality Medicines
Prospects for the Future
14
• Comprehensive scientific reports accessible to regulators as a basis for product approval from WHO and others. Public documents inadequate for decision making
• Ditto for inspection reports• Enhanced engagement/involvement of more
assessors/inspectors/analysts in WHO facilitated exchanges to equip regulators with the skills to make appropriate use of available information against resource availability
• Facilitate joint reviews at regional level
Protecting Your Right to Quality Medicines
Prospects for the Future
15
• Need for greater information sharing between regulators
• Need for added momentum for regional harmonisation activities
• Would lead to better utilisation of limited resources with agencies focussing on neglected areas of safety monitoring and market surveillance
Protecting Your Right to Quality Medicines
Conclusion
16